Related to FDA Clears Avid’s Amyloid Plaque Imaging Agent for Aiding Alzheimer Disease Diagnosis

• J&J to Initially Spend $1.5B for Elan’s Alzheimer’s Immunotherapy Program
  
• Scientists Peg 12-Peptide Cluster as Primary Toxin in Alzheimer’s Disease
  
• FDA Asks Spectrum Pharmaceuticals for Past Clinical Study Data to Help Expand Approval of NHL Drug
  
• Researchers Find Two miRNAs that Regulate Vascular Muscle Cell Plasticity
  
• Protalix’ Phase III Candidate for Gaucher’s May Fill the Treatment Gap due to Genzyme’s Plant Closure
  
• Shire’s Gaucher Disease Drug Candidate Being Considered by FDA
  
• Natural Antibodies to Amyloid Peptides Decrease with Age and Alzheimer’s Disease Progression
  
• Spinreact to Include AbD Serotec Antibodies in Clinical Diagnostic Kits
  
• FDA Gives Osmetech’s Cystic Fibrosis Genotyping Test a Thumbs Up
  
• Cognition Obtains $1.21M to Further Preclinical Molecules for Alzheimer’s Treatment
  
• FDA Says Erbitux No Good for Those with Certain K-ras Mutations
  
• FDA Clears Novartis Medication as Initial Therapy for Blood Pressure
  
• Axial Biotech Selects University of Utah Database to Develop Personalized Tests for Spine Disorders
  
• Cryopraxis to Assess Cryo-Cell's Menstrual Stem Cell Technology for Diagnosing Endometriosis
  
• QuantRx Creates Joint Venture with NuRx Focused on Point-of-Care Products
  
• Neurotez Scores $2.73M to Progress Preclinical Leptin Therapy for Alzheimer’s Disease
  
• FDA Gives Roche’s Avastin the Go-Ahead for Metastatic Renal Carcinoma
  
• Ichor and Partners Awarded $3.3M Grant to Develop Alzheimer’s Vaccine
  
• Researchers Identify New Alzheimer’s Risk Gene
  
• Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics